Document Detail

Aortic wave intensity analysis of ventricular-vascular interaction during incremental dobutamine infusion in adult sheep.
MedLine Citation:
PMID:  18024544     Owner:  NLM     Status:  MEDLINE    
This study undertook a detailed examination of the ventricular-vascular interaction of the predominant beta-adrenergic agonist dobutamine using wave intensity analysis. Eight anesthetized open-chest ewes were instrumented with an aortic micromanometer to measure central aortic blood pressure (P) and an ultrasonic flow probe to obtain ascending aortic blood velocity (U). Hemodynamics were recorded during incremental dobutamine infusion (0.5, 1, 2.5, 5, 7.5, and 10 Wave intensity (dI(W)) was calculated as the product of the rates of change of P and U with customized software using ensemble-averaged signals. Forward and backward components of dI(W), P, and U were determined after calculation of wave speed. As well as the typical initial forward compression wave (FCW), midsystolic backward compression wave (BCW), and late-systolic forward expansion wave (FEW(es)), two minor and previously unheralded waves were also detectable in the wave intensity profile at baseline. The first was an early systolic backward expansion wave (BEW), which reduced P but increased peak U. The second was a mid-systolic forward expansion wave (FEW(ms)), which reduced P and U. During dobutamine infusion FCW dI(W) increased 18-fold (P < 0.001), but BCW dI(W) rose 12-fold (P < 0.001) while FEW(es) dI(W) fell by 70% (P < 0.001). However, the latter changes were accompanied by a 44-fold increase in BEW dI(W) (P = 0.005) that augmented the initial aortic forward flow and a >100-fold rise in FEW(ms) dI(W) (P < 0.001) that produced earlier and enhanced aortic blood deceleration. These findings provide new insights into the ventricular-vascular interaction of dobutamine.
Daniel J Penny; Jonathan P Mynard; Joseph J Smolich
Related Documents :
12058794 - Potential for use of pulse wave analysis in determining the interaction between sildena...
17289174 - Negative association between serum levels of matrix metalloproteinases-2 and -9 and aor...
12624604 - Diastolic blood pressure is an important determinant of augmentation index and pulse wa...
12420194 - Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and...
3304404 - The effect of fetal heart rate on umbilical artery flow velocity waveforms.
3653084 - Bupivacaine accentuates the cardiovascular depressant effects of verapamil in conscious...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-11-16
Journal Detail:
Title:  American journal of physiology. Heart and circulatory physiology     Volume:  294     ISSN:  0363-6135     ISO Abbreviation:  Am. J. Physiol. Heart Circ. Physiol.     Publication Date:  2008 Jan 
Date Detail:
Created Date:  2008-01-14     Completed Date:  2008-02-28     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100901228     Medline TA:  Am J Physiol Heart Circ Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  H481-9     Citation Subset:  IM    
Department of Cardiology, Royal Children's Hospital, Flemington Road, Parkville, Victoria 3052, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Agonists / administration & dosage*
Aorta / drug effects*,  ultrasonography
Blood Flow Velocity / drug effects
Blood Pressure / drug effects*
Dobutamine / administration & dosage*
Dose-Response Relationship, Drug
Infusions, Intravenous
Laser-Doppler Flowmetry
Models, Cardiovascular
Regional Blood Flow
Signal Processing, Computer-Assisted*
Time Factors
Ventricular Function, Left / drug effects*
Reg. No./Substance:
0/Adrenergic beta-Agonists; 34368-04-2/Dobutamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of Cu,Zn-SOD in the synthesis of endogenous vasodilator hydrogen peroxide during reactive hyper...
Next Document:  Renal mitochondrial impairment is attenuated by AT1 blockade in experimental Type I diabetes.